Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-07-2010 | Original Article

Dosimetry for ¹³¹I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma

Authors: Ferdinand Sudbrock, Matthias Schmidt, Thorsten Simon, Wolfgang Eschner, Frank Berthold, Harald Schicha

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2010

Abstract

Purpose

Radiation dosimetry is a basic requirement for targeted radionuclide therapies (TRT) which have become of increasing interest in nuclear medicine. Despite the significant role of the radiopharmaceutical ¹³¹I-metaiodobenzylguanidine (MIBG) for the treatment of metastatic neuroblastoma, phaeochromocytoma and paraganglioma details for a reliable dosimetry are still sparse. This work presents our procedures, the dosimetric data and experiences with TRT using ¹³¹I-MIBG.

Methods

A total of 21 patients were treated with ¹³¹I-MIBG between 2004 and 2008 according to a clearly defined protocol. Whole-body absorbed doses were determined by a series of scintillation probe readings for all 21 cases. Tumour absorbed doses were calculated on the basis of quantitative imaging for an entity of 25 lesions investigated individually using the region of interest (ROI) technique based on five scans each.

Results

Typical whole-body absorbed doses are found in the region of 2 Gy (range: 1.0–2.9 Gy) whereas tumour absorbed doses in turn cover a span between 10 and 60 Gy. Nonetheless this variation of tumour absorbed doses is comparatively low.

Conclusion

The trial protocol in use is a substantial advancement in terms of reliable dosimetry. A clearly defined modus operandi for MIBG therapies should involve precisely described dosimetric procedures, e.g. a minimum of 20 whole-body measurements using a calibrated counter and at least four gamma camera scans over the whole period of the inpatient stay should be carried out. Calculation of tumour volumes is accomplished best via evaluation of SPECT and CT images.

Available only for authorised users

The highest value of 0.47 Gy/GBq is omitted here. The severe illness of this young boy did not allow more than five whole-body measurements and, what is more, the patient to detector distance could only roughly be kept constant. Quantitative imaging was impracticable.

Berger MJ. Distribution of absorbed doses around point sources of electrons and beta particles in water and other media. J Nucl Med 1971;Suppl 5:5–23.

Berger MJ, 1992. ESTAR, PSTAR and ASTAR: computer codes for calculating stopping-power and range tables for electrons, protons and helium ions, National Institute of Standards and Technology Report NISTIR 4999. http://physics.nist.gov/PhysRefData/Star/Text/contents.html. Accessed 1 Dec 2009.

Berthold F. NB2004 Trial Protocol (confidential), Gesellschaft für pädiatrische Onkologie und Hämatologie (Society of Pediatric Oncology and Hematology).

Bolster A, Hilditch TE, Wheldon TE, Gaze MN, Barrett A. Dosimetric considerations in 131I-MIBG therapy for neuroblastoma in children. Br J Radiol 1995;68:481–90.CrossRefPubMed

Buckley SE, Gaze MN, Chittenden S, Partridge M, Lancaster D, Pearson A, et al. Dosimetry for fractionated (131)I-mIBG therapies in patients with primary resistant high-risk neuroblastoma: preliminary results. Cancer Biother Radiopharm 2007;22:105–12.CrossRefPubMed

Buckley SE, Chittenden SJ, Saran F, Meller ST, Flux GD. Whole-body dosimetry for individualized treatment planning of 131I-MIBG radionuclide therapy for neuroblastoma. J Nucl Med 2009;50:1518–24.CrossRefPubMed

Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 2007;14:569–85.CrossRefPubMed

European Commission. Council directive 97/43/EURATOM of June 1997 on health protection of individuals against the dangers of ionising radiation in relation to medical exposure. Off J Eur Comm 1997;180:22–7.

O’Donoghue JA, Sgouros G, Divgi CR, Humm JL. Single-dose versus fractionated radioimmunotherapy: model comparisons for uniform tumor dosimetry. J Nucl Med 2000;41:538–47.PubMed

10.

Eckerman KF, Endo A. MIRD: radionuclide data and decay schemes. 2nd ed. Reston: Society of Nuclear Medicine; 2007.

11.

Fielding SL, Flower MA, Ackery D, Kemshead JT, Lashford LS, Lewis I. Dosimetry of iodine 131 metaiodobenzylguanidine for treatment of resistant neuroblastoma: results of a UK study. Eur J Nucl Med 1991;18:308–16.CrossRefPubMed

12.

Flower MA, Fielding SL. Radiation dosimetry for 131I-mIBG therapy of neuroblastoma. Phys Med Biol 1996;41:1933–40.CrossRefPubMed

13.

Flux GD, Guy MJ, Papvasileiou P, South C, Chittenden SJ, Flower MA, et al. Absorbed dose ratios for repeated therapy of neuroblastoma with I-131 mIBG. Cancer Biother Radiopharm 2003;18:81–7.CrossRefPubMed

14.

Gedik GK, Hoefnagel CA, Bais E, Valdés Olmos RA. 131I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2008;35:725–33.CrossRefPubMed

15.

Hoefnagel CA, Voûte PA, de Kraker J, Marcuse HR. Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 1987;28:308–14.PubMed

16.

Hoefnagel CA, de Kraker J, Valdés Olmos RA, Voûte PA. [131I] MIBG as a first line treatment in advanced neuroblastoma. Q J Nucl Med 1995;39:61–4.PubMed

17.

Kimmig B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, zum Winkel K. Scintigraphy of a neuroblastoma with I-131 meta-iodobenzylguanidine. J Nucl Med 1984;25:773–5.PubMed

18.

Klingebiel T, Treuner J, Ehninger G, Keller KD, Dopfer R, Feine U, et al. [131I]-metaiodobenzylguanidine in the treatment of metastatic neuroblastoma. Clinical, pharmacological and dosimetric aspects. Cancer Chemother Pharmacol 1989;25:143–8.CrossRefPubMed

19.

Kobe C, Eschner W, Sudbrock F, Weber I, Marx K, Dietlein M, et al. Graves’ disease and radioiodine therapy. Is success of ablation dependent on the achieved dose above 200 Gy? Nuklearmedizin 2008;47:13–7.PubMed

20.

Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004;45:1172–88.PubMed

21.

Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC. The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 1997;20:648–58.

22.

Mastrangelo R, Tornesello A, Mastrangelo S. Role of 131I-Metaiodobenzylguanidine in the treatment of neuroblastoma. Med Pediatr Oncol 1998;31:22–6.CrossRefPubMed

23.

Matthay K, Panina C, Huberty J, Price D, Glidden DV, Tang HR, et al. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG. J Nucl Med 2001;42:1713–21.PubMed

24.

Monsieurs MA, Thierens HM, Vral A, Brans B, De Ridder L, Dierckx RA. Patient dosimetry after 131I-MIBG therapy for neuroblastoma and carcinoid tumours. Nucl Med Commun 2001;22:367–74.CrossRefPubMed

25.

Monsieurs MA, Brans B, Bacher K, Dierckx R, Thierens H. Patient dosimetry for 131I-MIBG therapy for neuroendocrine tumours based on 123I-MIBG scans. Eur J Nucl Med Mol Imaging 2002;29:1581–7.CrossRefPubMed

26.

Oehme L, Dörr W, Wust P, Kotzerke J. Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation: consequences for dosimetry. Nuklearmedizin 2008;47:205–9. German.PubMed

27.

Bolster AA, Hilditch TE, Wheldon TE. Dosimetric models and S factors for radiation doses to the bladder wall in children receiving therapeutic iodine-131-MIBG. J Nucl Med 1995;36:1530–2.PubMed

28.

Schmidt M, Eschner W, Dietlein M, Theissen P, Schicha H. Established nuclear medicine techniques for tumour diagnosis (tumour SPECT): can they still compete with (18)F-FDG-PET? Nuklearmedizin 2005;44:37–48. German.PubMed

29.

Schmidt M, Simon T, Hero B, Eschner W, Dietlein M, Sudbrock F, et al. Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004. Nuklearmedizin 2006;45:145–51.PubMed

30.

Schmidt M, Simon T, Hero B, Schicha H, Berthold F. The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97. Eur J Cancer 2008;44:1552–58.CrossRefPubMed

31.

Shapiro B, Gross MD. Radiochemistry, biochemistry, and kinetics of 131I-metaiodobenzylguanidine (MIBG) and 123I-MIBG: clinical implication of the use of 123I-MIBG. Med Pediatr Oncol 1987;15:170–7.CrossRefPubMed

32.

Shapiro B, Sisson JC, Wieland DM, Mangner TJ, Zempel SM, Mudgett E, et al. Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 1991;35:269–76.PubMed

33.

Simon T, Hero B, Bongartz R, Schmidt M, Müller RP, Berthold F. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children >1 year with residual local disease. Strahlenther Onkol 2006;182:389–94.CrossRefPubMed

34.

Sisson JC, Shapiro B, Hutchinson RJ, Carey JE, Zasadny KR, Zempel SA, et al. Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine. Eur J Nucl Med 1994;21:46–52.CrossRefPubMed

35.

Sisson JC, Frager MS, Valk TW, Gross MD, Swanson DP, Wieland DM, et al. Scintigraphic localization of pheochromocytoma. N Engl J Med 1981;305:12–7.PubMedCrossRef

36.

Sgouros G. Toward patient-friendly cell-level dosimetry. J Nucl Med 2007;48:496–7.CrossRefPubMed

37.

Stabin MG, Brill AB. State of the art in nuclear medicine dose assessment. Semin Nucl Med 2008;38:308–20.CrossRefPubMed

38.

Sudbrock F, Eschner W, Schmidt M, Simon T, Hero B, Schicha H. Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG. Nuklearmedizin 2006;45:254–61. German.PubMed

39.

Sudbrock F, Boldt F, Kobe C, Eschner W, Schicha H. Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 1: diagnostic procedures. Nuklearmedizin 2008;47:267–74. German.PubMed

40.

Sudbrock F, Boldt F, Kobe C, Hammes J, Eschner W, Schicha H. Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: therapeutic procedures. Nuklearmedizin 2009;48:17–25. German.PubMed

41.

Tang HR, Da Silva AJ, Matthay K, Price DC, Huberty JP, Hawkins RA, et al. Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. J Nucl Med 2001;42:237–47.PubMed

42.

Tepmongkol S, Heyman S. 131I MIBG therapy in neuroblastoma: mechanisms, rationale, and current status. Med Pediatr Oncol 1999;32:427–31.CrossRefPubMed

43.

Tristam M, Alaamer AS, Fleming JS, Lewington VJ, Zivanovic MA. Iodine-131-metaiodobenzylguanidine dosimetry in cancer therapy: risk versus benefit. J Nucl Med 1996;37:1058–63.PubMed

44.

Unak P, Cetinkaya B. Absorbed dose estimates at the cellular level for 131I. Appl Radiat Isot 2005;62:861–9.CrossRefPubMed

45.

Vaidyanathan G, Zalutsky MR. No-carrier-added synthesis of meta-[131I]-iodobenzylguanidine. Appl Radiat Isot 1993;44:621–28.CrossRefPubMed

46.

WWW Table of radioactive isotopes. Decay data for iodine-131. http://nucleardata.nuclear.lu.se/NuclearData/toi/nuclide.asp?iZA=530131. Accessed 11 Nov 2009.

Title: Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma
Authors: Ferdinand Sudbrock
Matthias Schmidt
Thorsten Simon
Wolfgang Eschner
Frank Berthold
Harald Schicha
Publication date: 01-07-2010
Publisher: Springer-Verlag
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2010
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-010-1391-7

2024 ASCO Annual Meeting

Springer Medicine

Dosimetry for ¹³¹I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma

Abstract

Purpose

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2010

68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET

Clinical value of FDG PET/CT in the diagnosis of suspected recurrent ovarian cancer: is there an impact of FDG PET/CT on patient management?

A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues

Comment on: “FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging, version 1.0”

Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma

18F-FDG versus 11C-choline PET/CT for the imaging of advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy: the time period during which PET/CT can reliably detect non-recurrence